Cord Blood News Volume 7.25 | Jul 2 2015

A Simple, Xeno-Free Method for Oligodendrocyte Generation from Human Neural Stem Cells Derived from Umbilical Cord: Engagement of Gelatinases in Cell Commitment and Differentiation
Neural stem cells of human umbilical cord blood have been used to derive oligodendrocyte progenitors (OPCs) and subsequently to differentiate them into mature, GalC-expressing oligodendrocytes. Applied components of the extracellular matrix and the analogues of physiological substances known to increase glial commitment of neural stem cells have been shown to significantly increase the yield of the resulting OPC fraction. [J Tissue Eng Regen Med] Abstract

Second Allogeneic Hematopoietic Stem Cell Transplantation in Children with Severe Aplastic Anemia
The outcome of 55 children with severe aplastic anemia who received a second hematopoietic stem cell transplantation was retrospectively analyzed using the registration data of the Japanese Society for Hematopoietic Cell Transplantation. [Bone Marrow Transplant] Abstract

Lower Dose Anti-Thymocyte Globulin for GvHD Prophylaxis Results in Improved Survival after Allogeneic Stem Cell Transplantation
Anti-thymocyte globulin (ATG)-Fresenius at a dose of 60 mg/kg was standard GvHD prophylaxis in unrelated donor hematopoietic stem cell transplantation at our institution. Investigators changed to an incremental reduced dose regimen of 35 mg/kg and extended ATG prophylaxis to include older matched-related donor transplants considered to be at higher risk of GvHD. [Bone Marrow Transplant] Abstract

Human Umbilical Cord Mesenchymal Stromal Cell Transplantation in Myocardial Ischemia (HUC-HEART Trial). A Study Protocol of a Phase I/II, Controlled and Randomized Trial in Combination with Coronary Artery Bypass Grafting
The HUC-HEART trail is a Phase I/II, controlled, multicenter, randomized clinical study of the intramyocardial delivery of allogeneic human umbilical cord mesenchymal stem cells in patients with chronic ischemic cardiomyopathy. [Stem Cell Rev] Abstract

The Efficacy and Safety of Rabbit Anti-Thymocyte Globulin versus Rabbit Anti-T-Lymphocyte Globulin in Peripheral Blood Stem Cell Transplantation from Unrelated Donors
The records of 56 patients and 54 patients who received pre-transplant antithymocyte globulin (ATG)-Thymoglobulin at a total dose of 10 mg/kg and ATG- Fresenius at a total dose of 20 mg/kg, respectively, were retrospectively analyzed. [Leuk Lymphoma] Abstract

Equine Allogeneic Umbilical-Cord-Blood Mesenchymal Stromal Cells Reduce Synovial Fluid Nucleated Cell Count and Induce Mild Self-Limiting Inflammation when Evaluated in a LPS Induced Synovitis Model
Investigators evaluated the effect of intra-articular allogeneic umbilical-cord-blood-derived mesenchymal stromal cells using lipopolysaccharide (LPS) induced synovitis model. [Equine Vet J] Abstract

Isolation of Mesenchymal Stromal/Stem Cells from Small-Volume Umbilical Cord Blood Units that Do Not Qualify for the Banking System
Researchers examined the availability of freshly donated umbilical cord blood units that do not qualify for the Japanese banking system for transplantation because of their small volume as a source of mesenchymal stromal/stem cells. [Int J Hematol] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

Services and Research Collaboration Agreement between CellResearch Corporation Pte Ltd and the University of Colorado School of Medicine
CellResearch Corporation Pte Ltd. has entered into a Services and Research Collaboration Agreement with the University of Colorado School Of Medicine and ClinImmune Labs. The Service and Research Collaboration Agreement has the objective of achieving US FDA approval for therapeutic products of umbilical cord lining membrane progenitor/stem cells. [CellResearch Corporation Pte Ltd.] Press Release

CellResearch Corporation Receives New US Patent Approval for Exclusive Stem Cell Technology Amidst New Partnerships
CellResearch Corporation Pte Ltd. has received approval for its latest patent from the US Patent and Trademark Office. This patent allows the company’s continued efforts in developing Cord Lining Stem Cells [CellResearch Corporation Pte Ltd.] Press Release

From our sponsor: Learn about air-liquid interface culture for respiratory research. Watch the video.

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

NEW Director of Stem Cell Transplantation (University of Virginia)

Research Associate – Cell Separation (STEMCELL Technologies Inc.)

Principal Scientist – Hematopoietic Products (STEMCELL Technologies Inc.)

Regulatory Coordinator – Leukemia Research (Weill Cornell College of Medicine)

PhD Position – Drug Releasing, Nanostructured Biomaterials for Adult Stem Cells (Karlsruhe Institute of Technology)

Postdoctoral Fellow – Hematopoietic Stem Cell Biology (Harvard Medical School)

Postdoctoral Fellow – Immune Reconstitution in Hematopoietic Stem Cell Transplantation (Stanford University)

Postdoctoral Position – Epigenetic Regulation of Hematopoiesis and Leukemia (Karolinska Institutet)

Research Associate – Leukemia, Stem Cells and Development (Josep Carreras Leukemia Research Institute)

Recruit Top Talent: Reach more than 60,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.